AMC6156 not checked

Animuscure Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.”In the company’s words, NCT07072195 on ClinicalTrials.gov
Tested for
Sarcopenia in Elderly, Sarcopenia
Main trialPhase 2
“This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.”In the company’s words, NCT07072195 on ClinicalTrials.gov

Other drugs for Sarcopenia in Elderly

All 8 drugs for Sarcopenia in Elderly

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Oct 2026 A Study of AMC6156 in People With Sarcopenia
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow AMC6156

Following is part of Solo: you see every change to AMC6156 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in